Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a 15% increase compared to the same period last year[1]. - The company's revenue for the first half of 2023 was CNY 25,907,807.50, a decrease of 95.89% compared to CNY 629,790,353.02 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was a loss of CNY 841,429,076.81, compared to a profit of CNY 12,238,427.20 in the previous year, representing a decrease of 6,975.30%[19]. - The net cash flow from operating activities was a negative CNY 737,403,150.66, a 39.23% improvement from a negative CNY 1,213,518,523.05 in the same period last year[19]. - The total assets decreased by 13.70% to CNY 9,897,271,179.30 from CNY 11,468,958,286.71 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 12.38% to CNY 5,912,488,550.94 from CNY 6,748,089,902.12 at the end of the previous year[19]. - The basic earnings per share for the first half of 2023 was CNY -3.41, a decrease of 6,920.00% compared to CNY 0.05 in the same period last year[20]. - The diluted earnings per share also stood at CNY -3.41, reflecting the same significant decline as the basic earnings per share[20]. - The company reported a net profit after deducting non-recurring gains and losses of CNY -892,960,573.30, compared to CNY -56,768,490.38 in the previous year, marking an increase of 1,472.99%[19]. Research and Development - Research and development expenses increased by 25% to RMB 300 million, focusing on new vaccine technologies[1]. - The R&D expenditure as a percentage of revenue was 1,310.33%, an increase of 1,258.53 percentage points from 51.80% in the previous year[20]. - The company has developed five major technology platforms for vaccine research, showcasing advanced capabilities in viral vector vaccines, synthetic vaccines, protein structure design, mRNA technology, and formulation techniques[51][52][53][54][55]. - The company is focused on developing vaccines for significant clinical needs, including meningococcal, COVID-19, pertussis, pneumonia, tuberculosis, and shingles[25]. - The company has established a comprehensive vaccine R&D platform, securing over 30 invention patents and publishing in renowned medical journals[66]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[1]. - A strategic partnership was announced with a leading pharmaceutical company to enhance distribution channels, expected to increase sales by 15%[1]. - The company is exploring potential acquisitions to strengthen its product portfolio, with a budget of RMB 500 million allocated for this purpose[1]. - The company is actively monitoring the evolution of COVID-19 variants to inform its vaccine development strategy[29]. - The company has initiated international expansion, establishing vaccine production bases in countries like Pakistan and Mexico for localized COVID-19 vaccine production[70]. Regulatory and Compliance - The implementation of the Vaccine Administration Law in China has introduced stricter regulations across various stages of vaccine production and distribution, promoting industry consolidation and scale efficiency[47]. - The company has not reported any major asset or equity sales during the reporting period[113]. - The company has committed to transparency in reporting any changes in shareholding by its directors and senior management[138]. - The company has established a framework for accountability in case of any violations of the commitments made regarding shareholding[138]. Environmental Initiatives - The company invested 3.9846 million CNY in environmental protection during the reporting period[126]. - The company reduced carbon emissions by 3,478.6 tons through various measures, including energy audits and upgrading equipment for energy efficiency[131]. - The company has established an environmental management system and has not faced any administrative penalties for environmental violations during the reporting period[129]. - The company is focusing on low-carbon production and green energy-saving development concepts, enhancing corporate culture around green practices[131]. Shareholder and Governance - The company has approved a three-year dividend return plan for shareholders from 2023 to 2025[117]. - The company has initiated an employee stock ownership plan for 2023, which was approved in the recent shareholder meeting[117]. - The company has authorized the board to repurchase H shares and A shares, indicating a strategy to enhance shareholder value[118]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments[173]. Financial Health and Risks - The company faces risks related to core competitiveness, operational challenges, and financial risks due to the competitive nature of the vaccine industry and potential market changes[90][91][92]. - The company recorded an asset impairment loss of ¥711,717,561.04, an increase of 615,101,003.49 compared to the same period last year, primarily due to impairment provisions for inventory and long-term assets[102]. - The total amount of guarantees provided by the company during the reporting period (excluding guarantees to subsidiaries) is 790,000,000.00 RMB[187]. - The total guarantee balance at the end of the reporting period (excluding guarantees to subsidiaries) is 392,115,088.37 RMB, which accounts for 6.57% of the company's net assets[187].

康希诺生物股份公司 由于员工持股平台系公司控股股东、实际控制人之一朱涛先生的一致行动 人，根据中国证券监督管理委员会进一步规范股份减持行为的规定，并结合自身 关于公司控股股东、实际控制人的一致行动人 暨员工持股平台提前终止减持计划公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、减持计划的主要内容 2023 年 8 月 15 日，康希诺生物股份公司（以下简称"公司"）披露了《关 于公司控股股东、实际控制人的一致行动人暨员工持股平台减持股份计划公告》 （公告编号：2023-045）。 公司控股股东、实际控制人之一、执行董事、副总经理朱涛先生担任普通合 伙人的天津千益企业管理合伙企业（有限合伙）（以下简称"天津千益"）、天 津千睿企业管理合伙企业（有限合伙）（以下简称"天津千睿"）、天津千智企 业管理合伙企业（有限合伙）（以下简称"天津千智"，天津千益、天津千睿及 天津千智合称"员工持股平台"）计划通过集中竞价、大宗交易方式减持其所持 有的公司股份合计不超过 4,910,000 股，拟减持股份占公司总股本的比例约为 1 ...

董事會會議延期 香港，2023年8月28日 茲提述康希諾生物股份公司（「本公司」）日期為2023年8月16日之通告，內容有關 本公司董事（「董事」）會（「董事會」）會議將於2023年8月28日（星期一）舉行，藉 以（其中包括）考慮及批准本公司及其附屬公司截至2023年6月30日止六個月的中 期業績（「二零二三年中期業績」）及其刊發佈。 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士、朱 濤博士、Dongxu QIU博士及王靖女士；非執行董事林亮先生、梁頴宇女士及肖治 先生，以及獨立非執行董事韋少琨先生、辛珠女士、桂水發先生及劉建忠先生。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會謹此宣佈，批准二零二三年中期業績及其刊發佈的董事會會議將延期至 2023年8月30日（星期三）舉行。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-047 康希诺生物股份公司 自愿披露关于全资子公司对外投资的公告 投资金额：8,573,877 马来西亚令吉（以下简称"RM"）（根据认购协议签 署日中国人民银行公布的汇率，约合人民币 13,338,950.17 元）。对应标的公司 43,968,600 股股份，约占认购协议签署之日标的公司已发行总股本 10%。 相关风险提示：本次投资事项不构成关联交易，亦不构成《上市公司重 大资产重组管理办法》《科创板上市公司重大资产重组特别规定》规定的重大资 产重组情形。 一、对外投资概述 （一）对外投资的基本情况 公司基于自身战略发展规划、与标的公司之间的业务协同性以及对标的公司 投资价值的判断，为拓展东南亚市场，拟由康希诺香港与标的公司签署认购协议， 约定以 0.1950 RM/股（根据认购协议签署日中国人民银行公布的汇率，约合 0.3034 人民币元/股）的对价取得标的公司 43,968,600 股股份，约占认购协议签 署之日标的公司已发行总股本 10%。 （二）对外投资的决策与审批程序 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-046 康希诺生物股份公司 自愿披露关于重组新型冠状病毒疫苗（5型腺病毒载体） 获得印度尼西亚清真认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 概述 康希诺生物股份公司（以下简称"公司"）于近日收到印度尼西亚（以下简称 "印尼"）乌拉玛委员会食品、药品及化妆品评估机构（Assesment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia）授予重组新型冠状病毒疫苗（5 型腺病毒载体）克威莎®（以下简称"克威莎®"）的清真认证。 印尼约 87%的人口信奉伊斯兰教，是世界上穆斯林人口最多的国家。公开数 据显示，2022 年印尼共有 2.78 亿人口，人口总数位居全球第四位。根据印尼政 府的规定，印尼市场上的药品须经由清真产品保证机构（Halal Product Assurance Body）认可取得清真认证。此次获得清真认证，标志着克威莎®可以进入全球互 认的穆斯 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （股份代號：6185） 董事會會議日期 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事會 會議將於2023年8月28日（星期一）舉行，藉以（其中包括）考慮及批准本公司及其 附屬公司截至2023年6月30日止六個月的中期業績及其刊發佈，以及建議派發中 期股息（如有）。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 （於中華人民共和國註冊成立的股份有限公司） 香港，2023年8月16日 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士、朱 濤博士、Dongxu QIU博士及王靖女士；非執行董事林亮先生、梁頴宇女士及肖治 先生，以及獨立非執行董事韋少琨先生、辛珠女士、桂水發先生及劉建忠先生。 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-045 康希诺生物股份公司 关于公司控股股东、实际控制人的一致行动人 暨员工持股平台减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 公司控股股东、实际控制人之一、执行董事、副总经理朱涛先生担任普 通合伙人的天津千益企业管理合伙企业（有限合伙）（以下简称"天津千益"）、 天津千睿企业管理合伙企业（有限合伙）（以下简称"天津千睿"）、天津千智企业 管理合伙企业（有限合伙）（以下简称"天津千智"，天津千益、天津千睿及天津千 智合称"员工持股平台"）分别持有公司股份 3,474,600 股、3,299,475 股、1,207,150 股，占公司总股本 1.40%、1.33%、0.49%，为其于公司首次公开发行前取得的股 份，且已于 2023 年 8 月 14 日起上市流通。 减持计划的主要内容：天津千益、天津千睿、天津千智计划通过集中竞 价、大宗交易方式减持其所持有的公司股份合计不超过 4,910,000 股，拟减持股 份占 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-044 截至目前，暂无国内疫苗厂商研发的组分百白破疫苗获批上市，公司的婴幼 儿用 DTcP 定位即为进口替代。同时，该款疫苗的开发，也是青少年及成人用组 分百白破疫苗和组分百白破联合疫苗进一步研发的基础。组分百白破疫苗产品组 合将进一步丰富公司产品策略，提升公司核心竞争力。 二、临床试验相关情况 婴幼儿用 DTcP 开展的 I 期临床试验结果显示：该疫苗安全性良好，无 3 级 不良反应的发生，无与疫苗相关的严重不良事件（SAE）的发生。 III 期临床试验将基于 I 期临床获得的研究数据，评价该疫苗在 2 月龄、3 月 龄婴幼儿人群中接种的安全性及免疫原性，进行随机、盲法、阳性疫苗对照的临 床试验。 康希诺生物股份公司 自愿披露关于婴幼儿用吸附无细胞百（组分）白破联合疫苗 启动III期临床试验并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）的婴幼儿用吸附无细胞百（组分） 白破联合疫苗（以下简称"婴 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-043 康希诺生物股份公司 自愿披露关于与阿斯利康签署框架协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 康希诺生物股份公司（以下简称"公司"）与 AstraZeneca AB（以下简称"阿 斯利康"）签署了《产品供应合作框架协议》（以下简称"本协议"），公司将向 阿斯利康提供合同开发和生产服务以支持其 mRNA 疫苗项目，生产和供应特定 产品，并提供相关特定服务。本协议的具体实施内容和进度尚存在不确定性，敬 请投资者注意投资风险。 2、协议签订的决策程序 根据《上海证券交易所科创板股票上市规则》《公司章程》及《总经理工作 细则》的相关规定，本协议的签署属于公司总经理决策权限范围，无需提交公司 董事会及股东大会审议。 二、协议主要内容 1、协议日期：2023年8月7日 具体项目合作事宜将由双方或双方各自指定的附属公司另行签署具体的 项目协议。公司与阿斯利康合作的附属公司包括但不限于康希诺（上海）生物科 技有限公司、康希诺（上海）生物研 ...

Financial Performance - Operating revenue fell by 79.86% due to a significant decrease in demand for COVID-19 vaccines compared to last year[14] - Net profit attributable to shareholders decreased by 214.94%, leading to a loss for the company[14] - Basic and diluted earnings per share were both -0.57 RMB, compared to 0.49 RMB in the previous year[22] - The company reported a net loss of -170,199, compared to a profit of 114,295 in the same period last year, marking a significant shift in performance[33] - Total operating revenue for Q1 2023 was CNY 100,553 thousand, a decrease of 79.86% compared to CNY 499,355 thousand in Q1 2022[55] - Net profit attributable to shareholders for Q1 2023 was CNY -139,547 thousand, representing a decline of 214.94% year-over-year[60] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.57, a decrease of 216.33% compared to the previous year[60] Assets and Liabilities - Total assets decreased by 2.21% to RMB 11,215,389,000 compared to the previous year[13] - The total non-current assets increased to RMB 3,894,808,000, up from RMB 3,738,775,000[7] - The total assets amounted to 7,320,581, a decrease from 7,730,185, indicating a 5.3% decline[30] - The total liabilities as of Q1 2023 were CNY 4,137,354 thousand, a slight decrease from CNY 4,223,358 thousand in the previous year[54] - The company's total equity decreased to CNY 7,078,035 thousand from CNY 7,245,602 thousand year-over-year[54] - The total equity attributable to shareholders decreased by 2.03% to RMB 6,611,175,000[13] Cash Flow - The company reported a net cash flow from operating activities that was not applicable due to a decrease in cash paid for raw material procurement[14] - The net cash flow from operating activities was -345,404, a decrease from -598,148 in the previous year, indicating a 42.3% improvement[24] - Cash inflow from operating activities totaled CNY 140,298 thousand, compared to CNY 230,369 thousand in the same period last year[49] - Cash and cash equivalents at the end of the period stood at 2,843,894, down from 3,973,871, reflecting a 28.5% decrease[25] - Cash inflow from financing activities was 409,925, down from 517,416, reflecting a 20.8% decrease[24] Research and Development - R&D investment totaled RMB 150,871,000, representing an increase of 118.12 percentage points in R&D expenditure as a percentage of operating income[12] - Research and development expenses accounted for 118.12 percentage points increase in proportion to operating income, due to a larger decline in operating income compared to R&D expenses[49] Shareholder Information - The number of common shareholders at the end of the reporting period was 23,808[4] - The company has a total of 98,066,497 shares held by HKSCC NOMINEES LIMITED, accounting for 39.63% of total shares[4] - The accumulated undistributed profits reached -215,229,160.88, with total share capital at 247,449,899, indicating that the undistributed losses exceed one-third of the paid-in capital[29] Investment Activities - Total cash inflow from investing activities was 2,787,236, up from 2,135,294, representing a 30.6% increase[24] - The net cash flow from investing activities was -172,009, an improvement from -894,010, showing a 80.7% reduction in losses[24] Foreign Exchange - The company experienced a foreign exchange loss of -19,486, compared to -12,150 in the previous year, indicating increased volatility in currency impacts[24] Future Plans - The company plans to issue Global Depository Receipts (GDR) to enhance international financing channels and brand image[28]